Multi-scale tissue architecture analysis of favorable-risk prostate cancer: Correlation with biochemical recurrence.
Biochemical recurrence
Image biomarkers
Prostate cancer
Tissue architecture analysis
Journal
Investigative and clinical urology
ISSN: 2466-054X
Titre abrégé: Investig Clin Urol
Pays: Korea (South)
ID NLM: 101674989
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
13
01
2020
revised:
06
03
2020
accepted:
24
03
2020
pubmed:
1
8
2020
medline:
4
6
2021
entrez:
1
8
2020
Statut:
ppublish
Résumé
Prostate cancer (PCa) with biopsy-based grade group (GG) 1 or 2 characteristics has a favorable outcome, yet some cases still progress after radical prostatectomy and present with biochemical recurrence (BCR). We hypothesized that the multi-scale tissue architecture (MSTA) analysis score would correlate with the aggressive PCa phenotype and could be used as a tool for risk assessment to improve the management of patients with favorable-risk PCa. MSTA was evaluated in needle-biopsy samples from 115 patients with favorable-risk PCa, as defined by GG1 and GG2, a prostate-specific antigen (PSA) level of <10 ng/mL, a clinical stage of cT1c to cT2b, and general Gleason GG (GGG) and expert pathologist-assessed GG (EGG). Algorithms based on Voronoi diagrams were applied to all Feulgen-thionin-stained diagnostic areas. One hundred tissue architecture features were calculated and an MSTA score, a linear combination of the most discriminant features, was generated. Correlation of MSTA score with BCR and other clinical variables was investigated. In a univariate regression model, EGG, clinical stage, and MSTA were significant predictors of BCR (respective p-values: 0.0016, 0.016, and 0.028). Survival analysis showed that patients with a high MSTA score were more likely to experience BCR than were patients with a low MSTA score (odds ratio, 2.9). Combining MSTA with GG assessment resulted in a significant stratification of risk for BCR. MSTA score could be used as an objective adjunct risk stratification tool to pathologist assessments and could improve the management of patients with favorable-risk PCa.
Identifiants
pubmed: 32734723
pii: 61.e43
doi: 10.4111/icu.20200018
pmc: PMC7458870
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
482-490Informations de copyright
© The Korean Urological Association, 2020.
Déclaration de conflit d'intérêts
The authors have nothing to disclose.
Références
Anal Cell Pathol. 2000;21(2):71-86
pubmed: 11310643
Acta Histochem. 2013 Jul;115(6):527-32
pubmed: 23313439
Anal Quant Cytopathol Histpathol. 2016 Apr;38(2):59-69
pubmed: 27386626
BJU Int. 2012 Feb;109 Suppl 1:22-9
pubmed: 22239226
Anal Quant Cytol Histol. 2007 Oct;29(5):296-308
pubmed: 17987810
Comput Methods Programs Biomed. 2005 Feb;77(2):99-113
pubmed: 15652632
BJU Int. 2005 Jun;95(8):1146-52
pubmed: 15877724
Arch Pathol Lab Med. 2012 Apr;136(4):426-34
pubmed: 22458905
J Cancer Res Clin Oncol. 2008 Oct;134(10):1071-8
pubmed: 18392850
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Br J Cancer. 2017 Jul 25;117(3):367-375
pubmed: 28618431
J Natl Cancer Inst. 2010 May 5;102(9):605-13
pubmed: 20413742
Lancet Oncol. 2014 Sep;15(10):1109-18
pubmed: 25163905
Eur Urol. 2015 Jun;67(6):1168-1176
pubmed: 24996687
Cytometry A. 2017 Dec;91(12):1164-1174
pubmed: 29194951
Nat Med. 2016 Jan;22(1):105-13
pubmed: 26618723
Nat Genet. 2015 Apr;47(4):367-372
pubmed: 25730763
Oncology (Williston Park). 1997 Aug;11(8):1133-9; discussion 1139-40, 1143
pubmed: 9268976
Int Braz J Urol. 2007 Sep-Oct;33(5):639-46; discussion 647-51
pubmed: 17980061
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
IEEE Rev Biomed Eng. 2015;8:98-113
pubmed: 25055385